| Girishkumar Popatlal Shah, MD | |
|
835 Pride Dr, Ste B, Hammond, LA 70401-9527 | |
| (985) 543-4333 | |
| (985) 543-4817 |
| Full Name | Girishkumar Popatlal Shah |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 45 Years |
| Location | 835 Pride Dr, Hammond, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538210109 | NPI | - | NPPES |
| 1914983 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 07754R (Louisiana) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Florida Parishes Human Services Authority | 0446578215 | 30 |
News Archive
Endo Pharmaceuticals announced today that it has entered into a collaboration agreement with European-based Orion Corporation for the discovery, development and commercialization of assets in Oncology.
A set of 7 symptoms, considered together, can be used to maximize detection of COVID-19 in the community, according to a new paper published this week in PLOS Medicine by Marc Chadeau-Hyam and Paul Elliott of Imperial College London, UK, and colleagues.
A new study from MIT implicates a family of RNA-binding proteins in the regulation of cancer, particularly in a subtype of breast cancer. These proteins, known as Musashi proteins, can force cells into a state associated with increased proliferation.
Amakem NV, a kinase platform company focusing on ophthalmology, today announces that it has initiated a Phase 2a proof of concept study of its novel Rho Kinase (ROCK) inhibitor, AMA0076, in patients with glaucoma and ocular hypertension.
› Verified 2 days ago
| Entity Name | Florida Parishes Human Services Authority |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679128292 PECOS PAC ID: 0446578215 Enrollment ID: O20150408001452 |
News Archive
Endo Pharmaceuticals announced today that it has entered into a collaboration agreement with European-based Orion Corporation for the discovery, development and commercialization of assets in Oncology.
A set of 7 symptoms, considered together, can be used to maximize detection of COVID-19 in the community, according to a new paper published this week in PLOS Medicine by Marc Chadeau-Hyam and Paul Elliott of Imperial College London, UK, and colleagues.
A new study from MIT implicates a family of RNA-binding proteins in the regulation of cancer, particularly in a subtype of breast cancer. These proteins, known as Musashi proteins, can force cells into a state associated with increased proliferation.
Amakem NV, a kinase platform company focusing on ophthalmology, today announces that it has initiated a Phase 2a proof of concept study of its novel Rho Kinase (ROCK) inhibitor, AMA0076, in patients with glaucoma and ocular hypertension.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Girishkumar Popatlal Shah, MD 23 Piper Ln, Mandeville, LA 70448-3455 Ph: (985) 626-1487 | Girishkumar Popatlal Shah, MD 835 Pride Dr, Ste B, Hammond, LA 70401-9527 Ph: (985) 543-4333 |
News Archive
Endo Pharmaceuticals announced today that it has entered into a collaboration agreement with European-based Orion Corporation for the discovery, development and commercialization of assets in Oncology.
A set of 7 symptoms, considered together, can be used to maximize detection of COVID-19 in the community, according to a new paper published this week in PLOS Medicine by Marc Chadeau-Hyam and Paul Elliott of Imperial College London, UK, and colleagues.
A new study from MIT implicates a family of RNA-binding proteins in the regulation of cancer, particularly in a subtype of breast cancer. These proteins, known as Musashi proteins, can force cells into a state associated with increased proliferation.
Amakem NV, a kinase platform company focusing on ophthalmology, today announces that it has initiated a Phase 2a proof of concept study of its novel Rho Kinase (ROCK) inhibitor, AMA0076, in patients with glaucoma and ocular hypertension.
› Verified 2 days ago
Socrates Zapata-campusano, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 15784 Medical Arts Dr Ste A, Hammond, LA 70403 Phone: 985-230-7525 Fax: 985-230-7535 | |
Dr. Beatrice Groene, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 15785 Medical Arts Dr, Hammond, LA 70403 Phone: 985-543-4080 | |
Patricia Maria Morgan, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 42131 Veterans Ave, Suite 100, Hammond, LA 70403 Phone: 985-345-7246 Fax: 985-345-7249 | |
Ann J. Arretteig, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 835 Pride Dr Ste B, Hammond, LA 70401 Phone: 985-543-4333 Fax: 985-543-4817 | |
Dr. Richard Peter Strobach, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 15752 Professional Plaza Street, Hammond, LA 70403 Phone: 985-542-0052 Fax: 985-542-4928 | |
Schoener Laprairie, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 835 Pride Drive, Suite B, Hammond, LA 70401 Phone: 985-543-4333 Fax: 985-543-4817 | |
Suzanne Hall Calhoun, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 835 Pride Dr Ste B, Hammond, LA 70401 Phone: 225-359-9315 Fax: 225-359-9365 |